Myelodysplastic syndromes: recent advances.

[1]  A. Biondi,et al.  Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. , 2001, Cancer genetics and cytogenetics.

[2]  L. Kearney,et al.  Combined immunophenotyping and FISH identifies the involvement of B‐cells in 5q‐ syndrome , 2000, Genes, chromosomes & cancer.

[3]  S. E. Jacobsen,et al.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.

[4]  G. Meloni,et al.  Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2000, British journal of haematology.

[5]  M. Cazzola.  Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. , 2000, International journal of hematology.

[6]  P G Mori,et al.  Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. , 2000, Blood.

[7]  O. Ottmann,et al.  Cytokine therapy for myelodysplastic syndrome , 2000, Current opinion in hematology.

[8]  B. Johansson,et al.  Smoking and myelodysplastic syndromes. , 2000, Epidemiology.

[9]  Z. Arbieva,et al.  Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. , 2000, Blood.

[10]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.

[11]  L. Nagarajan,et al.  Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. , 2000, Blood.

[12]  H. Deeg,et al.  Hemopoietic stem cell transplantation for myelodysplastic syndrome , 2000, Current opinion in oncology.

[13]  H. Deeg,et al.  Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.

[14]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[15]  Y. Kwong,et al.  Familial acute myeloid leukemia with monosomy 7: late onset and involvement of a multipotential progenitor cell. , 2000, Cancer genetics and cytogenetics.

[16]  P. Emanuel,et al.  Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. , 2000, Blood.

[17]  K. Helzlsouer,et al.  Use of Hair Dyes, Hematopoietic Neoplasms, and Lymphomas: A Literature Review. I. Leukemias and Myelodysplastic Syndromes , 2000, Cancer investigation.

[18]  L. Pagano,et al.  Chemotherapy of Secondary Leukemias , 2000, Leukemia & lymphoma.

[19]  Benz,et al.  Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.

[20]  D. A. Stafford,et al.  Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. , 1997, Blood.

[21]  F. Facchetti,et al.  Expression of CD34 by megakaryocytes in myelodysplastic syndromes. , 2000, Haematologica.

[22]  T. Tauchi,et al.  Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase. , 2000, Haematologica.

[23]  J. Hernández,et al.  Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. , 2000, Haematologica.

[24]  V. Santini,et al.  Amifostine in the treatment of low-risk myelodysplastic syndromes. , 2000, Haematologica.

[25]  C. Rosenfeld,et al.  A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies , 2000, Leukemia.

[26]  J. E. Guimarães,et al.  Differences in phenotype, growth factor requirements, pattern of expression of adhesion molecules and rate of apoptosis displayed by three new myeloid sister leukemic cell lines. , 2000, Haematologica.

[27]  A. Barrett,et al.  Achievements in Understanding and Treatment of Myelodysplastic Syndromes. , 2000, Hematology. American Society of Hematology. Education Program.

[28]  B. Rotoli,et al.  Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. , 2000, Haematologica.

[29]  E. Estey,et al.  Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. , 2000, Haematologica.

[30]  J. Román,et al.  A case of atypical myelodysplastic syndrome with a novel reciprocal translocation t(1;12)(q21;p13) , 2000, Haematologica.

[31]  A. Corso,et al.  Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case report. , 2000, Haematologica.

[32]  C. Peterson,et al.  Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin. , 2000, Haematologica.

[33]  C. Chiodino,et al.  Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? , 2000, Haematologica.

[34]  A. Pecci,et al.  Dihydrofolate reductase activity in the erythroblasts of patients with 5q- syndrome. , 2000, Haematologica.

[35]  V. Rosti.  The molecular basis of paroxysmal nocturnal hemoglobinuria. , 2000, Haematologica.

[36]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  F. Ferrara,et al.  Fludarabine, cytarabine, and granulocyte‐colony stimulating factor for the treatment of high risk myelodysplastic syndromes , 1999, Cancer.

[39]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[40]  E. Estey,et al.  Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. McBride,et al.  A population‐based study of childhood myelodysplastic syndrome in British Columbia, Canada , 1999, British journal of haematology.

[42]  Y. Yoshida.  The aplasia-myelodysplasia enigma: a re-emerging question. , 1999, International journal of hematology.

[43]  M. Taniwaki,et al.  Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype , 1999, Leukemia.

[44]  Johnson M Liu,et al.  Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.

[45]  Y. Saunthararajah,et al.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.

[46]  A. Green.  The pathogenesis and management of essential thrombocythaemia. , 1999, Haematologica.

[47]  B. Lange,et al.  Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. , 1999, Blood.

[48]  M. André,et al.  DNA demethylating therapy in MDS: The experience with 5-AZA-2 '-deoxycytidine (decitabine). , 1999 .

[49]  H. Deeg,et al.  Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. , 1999, Haematologica.

[50]  Beyond the FAB classification for myelodysplastic syndromes. , 1999, Haematologica.

[51]  H. Mizoguchi,et al.  Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. , 1999, Leukemia research.

[52]  E. Ascari,et al.  The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. , 1999, Haematologica.

[53]  K. Metze,et al.  The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. , 1999, Haematologica.

[54]  F. Giles,et al.  The potential of amifostine: from cytoprotectant to therapeutic agent. , 1999, Haematologica.

[55]  Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes. , 1999, Haematologica.

[56]  J. Juncà,et al.  Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. , 1999, Haematologica.

[57]  S. Magalhães,et al.  p53 overexpression in refractory anemia. An immunohistochemical analysis of bone marrow biopsies. , 1999, Haematologica.

[58]  P. Iversen,et al.  Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. , 1998, Blood.

[59]  Hepburn,et al.  Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients , 1998, British journal of haematology.

[60]  C. Eaves,et al.  Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. , 1998, Blood.

[61]  S. Scherer,et al.  Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. , 1998, Blood.

[62]  C. de Angeli,et al.  Exposure to myelotoxic agents and myelodysplasia: case–control study and correlation with clinicobiological findings , 1998, British journal of haematology.

[63]  D. Horsman,et al.  Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. , 1998, Blood.

[64]  D. Kirsch,et al.  Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Davis,et al.  Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.

[66]  Caillot,et al.  Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.

[67]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[68]  K. Shannon,et al.  Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. , 1998, Blood.

[69]  A. Gratwohl,et al.  Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.

[70]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[71]  P. Nowell,et al.  Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Cazzola,et al.  Red blood cell precursor mass as an independent determinant of serum erythropoietin level. , 1998, Blood.

[73]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[74]  V. Najfeld,et al.  Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer , 1998, Leukemia.

[75]  J. Čermák,et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.

[76]  D. Gilliland,et al.  X-inactivation analysis in the 1990s: promise and potential problems , 1998, Leukemia.

[77]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.

[78]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[79]  C. Preudhomme,et al.  17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. , 1998, Blood.

[80]  Luoping Zhang,et al.  Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes. , 1998, Leukemia research.

[81]  Y Yoshida,et al.  Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. , 1998, Haematologica.

[82]  E. Estey,et al.  Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1998, Leukemia & lymphoma.

[83]  U. Germing,et al.  Increasing incidence of myelodysplastic syndromes: real or fictitious? , 1998, Leukemia research.

[84]  M. Cazzola,et al.  A patient-oriented approach to treatment of myelodysplastic syndromes. , 1998, Haematologica.

[85]  K. Shannon,et al.  Mutations of the NF 1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis , Type 1 , 1998 .

[86]  P. Greenberg,et al.  Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.

[87]  A. Aventín,et al.  Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. , 1998, Blood.

[88]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[89]  B. Czepulkowski,et al.  Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia , 1997, British journal of haematology.

[90]  G. Nucifora.  The EVI1 gene in myeloid leukemia , 1997, Leukemia.

[91]  K. Hirokawa,et al.  Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.

[92]  M. Labopin,et al.  Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS , 1997 .

[93]  N. Zhao,et al.  dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53 , 1997, Genes, chromosomes & cancer.

[94]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.

[95]  A. List,et al.  Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. , 1997, Blood.

[96]  P. Thall,et al.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.

[97]  C. Pui,et al.  Juvenile myelomonocytic leukemia. , 1997, Blood.

[98]  M. Cazzola,et al.  Use of recombinant human erythropoietin outside the setting of uremia. , 1997, Blood.

[99]  J. D. Vos,et al.  Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.

[100]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.

[101]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .

[102]  W. Hiddemann,et al.  S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes , 1997, Annals of Hematology.

[103]  J. G. van den Tweel,et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.

[104]  J. Sierra,et al.  192 Bone marrow transplantation for myelodysplasia: The IBMTR data , 1997 .

[105]  F. Aversa,et al.  194 Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients , 1997 .

[106]  U. Germing,et al.  169 Aggressive chemotherapy in MDS: The Düsseldorf experience , 1997 .

[107]  M. Slovak,et al.  Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. , 1997, American journal of clinical pathology.

[108]  R. Storb,et al.  Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. , 1997, Blood.

[109]  S. Scherer,et al.  Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. , 1997, Blood.

[110]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[111]  L. Michaux,et al.  5q-, twenty-five years later: a synopsis. , 1997, Cancer genetics and cytogenetics.

[112]  W. Friedrich,et al.  Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  A. Ganser,et al.  Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. , 1997, Leukemia & lymphoma.

[114]  R. Darley,et al.  The molecular basis of myelodysplastic syndromes. , 1997, Haematologica.

[115]  D. Ross.  Metabolic basis of benzene toxicity , 1996, European journal of haematology. Supplementum.

[116]  S. Ben-Neriah,et al.  Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. , 1996, Blood.

[117]  Martyn T. Smith,et al.  Overview of benzene‐induced aplastic anaemia , 1996, European journal of haematology. Supplementum.

[118]  F. Benvenuto,et al.  IN VIVO MOBILIZATION OF KARYOTyPICALLY NORMAL PERIPHERAL BLOOD PROGENITOR CELLS IN HIGH‐RISK MDS, SECONDARY OR THERAPY‐RELATED ACUTE MYELOGENOUS LEUKAEMIA , 1996, British journal of haematology.

[119]  E. Estey,et al.  Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. , 1996, Blood.

[120]  C. Bloomfield,et al.  Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[122]  H. Hasle,et al.  Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. , 1996, Leukemia.

[123]  Marie-Cécile Michallet,et al.  Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle , 1996 .

[124]  H. Koeffler,et al.  Differentiation therapy in myelodysplastic syndromes. , 1996, Seminars in hematology.

[125]  T. Petrella,et al.  Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. , 1996, British Journal of Cancer.

[126]  M. Leppert,et al.  Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. , 1996, Blood.

[127]  P. Greenberg,et al.  Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. , 1996, Blood.

[128]  S. Scherer,et al.  Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia. , 1996, Blood.

[129]  P. Morel,et al.  Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.

[130]  K. Kojima,et al.  Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.

[131]  K. Sullivan,et al.  Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.

[132]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[133]  F. Leeuwen.  4 Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment , 1996 .

[134]  N. Zeleznik-Le,et al.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. , 1996, Blood.

[135]  T. Jacks,et al.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells , 1996, Nature Genetics.

[136]  A. Pession,et al.  Role of allogeneic bone marrow transplantation from an HLA‐identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia , 1996, British journal of haematology.

[137]  G. Verhoef,et al.  Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor‐risk myelodysplastic syndromes , 1996, British journal of haematology.

[138]  F. Appelbaum,et al.  Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  K. Sullivan,et al.  Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. , 1996, Blood.

[140]  R. Latagliata,et al.  Erythropoietin in myelodysplastic syndromes: durable response in a young patient. , 1996, Haematologica.

[141]  C. Chastang,et al.  Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. , 1996, Blood.

[142]  C. Mecucci,et al.  Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. , 1996, Cancer genetics and cytogenetics.

[143]  F. V. van Leeuwen.  Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. , 1996, Bailliere's clinical haematology.

[144]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.

[145]  A. Nademanee,et al.  Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  G. Verhoef,et al.  Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. , 1995, Blood.

[147]  H. Zwierzina,et al.  Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). , 1995, Leukemia.

[148]  P. Nowell,et al.  Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[149]  G. Dini,et al.  Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. , 1995, Blood.

[150]  P. Marynen,et al.  TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). , 1995, Blood.

[151]  K. Shannon,et al.  Childhood monosomy 7: epidemiology, biology, and mechanistic implications. , 1995, Blood.

[152]  C. Lorthois,et al.  Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. , 1995, Leukemia.

[153]  E. Wattel,et al.  Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.

[154]  M. Carlsson,et al.  Incidence of myelodysplastic syndromes in a Swedish population , 1995, European journal of haematology.

[155]  F. Locatelli,et al.  Myelodysplastic syndromes: the pediatric point of view. , 1995, Haematologica.

[156]  C. Mecucci.  FISH (fluorescent in situ hybridization): the second youth of cytogenetics. , 1995, Haematologica.

[157]  P. Emanuel,et al.  A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. , 1994, The New England journal of medicine.

[158]  K. Shannon,et al.  Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras , 1994 .

[159]  J. Boultwood,et al.  The 5q-syndrome. , 1994, Blood.

[160]  R. Gutzmer,et al.  Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients , 1994, European journal of haematology.

[161]  D. T. Goodhead,et al.  α-particle-induced chromosomal instability in human bone marrow cells , 1994, The Lancet.

[162]  R. Gale,et al.  Hematologic Abnormalities in Fanconi Anemia: An International Fanconi Anemia Registry Study , 1994 .

[163]  P. Greenberg,et al.  Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. , 1994, Blood.

[164]  D. Oscier,et al.  Establishing the incidence of myelodysplastic syndrome , 1994 .

[165]  C. Preudhomme,et al.  Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. , 1994, Leukemia.

[166]  A. Green,et al.  Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. , 1994, Blood.

[167]  P. Thall,et al.  Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  N. Young,et al.  Gamma-Interferon Gene Expression in the Bone Marrow of Patients with Aplastic Anemia , 1994, Annals of Internal Medicine.

[169]  P. O'Connell,et al.  Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.

[170]  G. Brodeur.  The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. , 1994, The New England journal of medicine.

[171]  Yoshiyuki Kobayashi,et al.  Trilineage recovery by combination therapy with recombinant human granulocyte colony‐stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia , 1994, Stem cells.

[172]  H. Johnsen,et al.  Recombinant human granulocyte‐macrophage colony‐stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes , 1993, American journal of hematology.

[173]  A. Tichelli,et al.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.

[174]  I. Dybedal,et al.  A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. , 1993, Leukemia & lymphoma.

[175]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[176]  J. Wallvik,et al.  Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. , 1993, Leukemia.

[177]  J. Buckley,et al.  Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  P. Greenberg,et al.  Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. , 1993, Blood.

[179]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[180]  R. Espinosa,et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[181]  S. Asano,et al.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.

[182]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[183]  A. Kanamaru,et al.  [Bone marrow transplantation for refractory anemia]. , 1993, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[184]  R. Berger,et al.  Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders. , 1993, Leukemia.

[185]  C. Campagnoli,et al.  Bone marrow transplantation from unrelated donor in myelodysplastic syndromes. , 1993, Bone marrow transplantation.

[186]  Y. Kan,et al.  Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. , 1992, Genomics.

[187]  M. Mittelman,et al.  Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. , 1992, Blood.

[188]  O. Haas,et al.  Experience in pediatric myelodysplastic syndromes. , 1992, Hematology/oncology clinics of North America.

[189]  C. Bloomfield,et al.  Trisomy 13 in acute leukemia. , 1992, Leukemia & lymphoma.

[190]  P. O'Connell,et al.  Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. , 1992, Blood.

[191]  Z. Estrov,et al.  Central role of tumour necrosis factor, GM‐CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia , 1992, British journal of haematology.

[192]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[193]  G Barosi,et al.  Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. , 1992, Blood.

[194]  P. Emanuel,et al.  The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. , 1991, Experimental hematology.

[195]  D. Anderson,et al.  The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. , 1991, British journal of industrial medicine.

[196]  P. Morel,et al.  Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.

[197]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[198]  F. Tamanoi,et al.  The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae , 1990, Cell.

[199]  R. Gelber,et al.  Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  C. Haanen,et al.  Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.

[201]  S. Raimondi,et al.  Myeloid neoplasia in children treated for solid tumours , 1990, The Lancet.

[202]  B. Cheson,et al.  The myelodysplastic syndromes: current approaches to therapy. , 1990, Annals of internal medicine.

[203]  M. Sanz,et al.  Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors , 1990, British journal of haematology.

[204]  R. Storb,et al.  Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. , 1990 .

[205]  A. Gratwohl,et al.  Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.

[206]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[207]  J. Goasguen,et al.  Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system. , 1990, Leukemia research.

[208]  P. Emanuel,et al.  Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. , 1989, Blood.

[209]  F. Behm,et al.  Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.

[210]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[211]  E. Guinan,et al.  Bone marrow transplantation for children with myelodysplastic syndromes. , 1989, Blood.

[212]  R. Truitt,et al.  Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  R. Larson,et al.  Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. , 1988, Blood.

[214]  F. Mitelman,et al.  Bone marrow karyotype and prognosis in primary myelodysplastic syndromes , 1988, European journal of haematology.

[215]  R. Parmley,et al.  Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia. , 1988, Experimental hematology.

[216]  J. Bennett.  Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group. , 1988, Cancer genetics and cytogenetics.

[217]  K. Sullivan,et al.  Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. , 1988, Blood.

[218]  J. Gmür.  [Allogeneic bone marrow transplantation]. , 1988, Therapeutische Umschau. Revue therapeutique.

[219]  A. Avilés,et al.  [Treatment of myelodysplastic syndromes with danazol]. , 1988, Archivos de investigacion medica.

[220]  Z. Estrov,et al.  Juvenile Chronic Myelogenous Leukemia , 1988, The American journal of pediatric hematology/oncology.

[221]  D. Oscier.  Myelodysplastic syndromes. , 2007, Bailliere's clinical haematology.

[222]  B. Coiffier,et al.  Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients , 1987, Cancer.

[223]  Z. Estrov,et al.  The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  P. Bierman,et al.  Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  Z. Estrov,et al.  Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. , 1987, Blood.

[226]  W. Moloney,et al.  Radiogenic leukemia revisited. , 1987, Blood.

[227]  L. Parapia,et al.  Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts , 1987, European journal of haematology.

[228]  D. Oscier.  5 Myelodysplastic syndromes , 1987 .

[229]  B. Cheson,et al.  Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. , 1987, Seminars in oncology.

[230]  J. Pedersen‐Bjergaard,et al.  Cytogenetic characteristics of therapy‐related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases , 1987, British journal of haematology.

[231]  G. Tricot,et al.  A chromosomal profile of polycythemia vera. , 1987, Cancer genetics and cytogenetics.

[232]  G. Masera,et al.  Myelodysplastic Syndromes in Childhood: Report of 21 Patients from Italy and West Germany , 1987, The American journal of pediatric hematology/oncology.

[233]  R. Larson,et al.  High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.

[234]  Z. Estrov,et al.  Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. , 1986, Blood.

[235]  G. Tricot,et al.  An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes , 1986, British journal of haematology.

[236]  G. Tricot,et al.  The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.

[237]  G. Tricot,et al.  Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis , 1985, British journal of haematology.

[238]  G. Tricot,et al.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.

[239]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[240]  H. Deeg,et al.  Allogeneic marrow transplantation in the treatment of preleukemia. , 1984, Annals of internal medicine.

[241]  Denis R. Miller,et al.  Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors , 1984, Cancer.

[242]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[243]  B. Lange,et al.  Preleukemia in children. , 1981, The Journal of pediatrics.

[244]  R. Mertelsmann,et al.  Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. , 1980, Blood.

[245]  J. Lilleyman,et al.  Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. , 1977, Blood.

[246]  A. Chapelle,et al.  Defective chemotaxis in monosomy-7 , 1977, Nature.

[247]  J. Fryns,et al.  Distinct haematological disorder with deletion of long arm of No. 5 chromosome , 1974, Nature.